Neuroendocrine tumors of stomach. Modern classification


Cite item

Full Text

Abstract

Neuroendocrine tumors (NETs) of the stomach include a wide range of neoplasm with different variants of the disease, various approaches to the treatment and different prognosis. The incidence is quite low - NETs of stomach accounted for only 9% of all gastrointestinal (GI) NETs and 0,3% of all tumors of stomach. Gastric NETs have significantly different biological and clinical characteristics from other carcinoids developing from “foregut”. The distinctive features of these tumors attract the attention of many scientists. Modern methods of instrumental diagnostics, as well as histological, immunohistochemical and molecular genetic, make it possible to assess malignant potential of the tumor and individualize treatment in every case. In this article we have tried to bring the information about NET with high and poor differentiation, which include small and large cell types together.

About the authors

Ivan N. Peregorodiev

N.N. Blokhin Russian Cancer Research Center

Email: ivan.peregorodiev@gmail.com
postgraduate student of the Department of abdominal oncology Moscow, 115478, Russian Federation

V. Y Bokhian

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

V. V Delektorskaya

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

I. S Stilidi

N.N. Blokhin Russian Cancer Research Center

Moscow, 115478, Russian Federation

References

  1. Tsikitis V.L., Wertheim B.C., Guerrero M.A. Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: A seer. Analysis. 2012; 3: 292-302.
  2. Lubarsch O. Ueber den primaren Krebs des Ileum, nebstBemerkungenuber das gleichzeitige Vorkommenvon Krebs und Tuberkolose. Virchows Arch. 1888; 111: 280-317.
  3. Oberndorfer S. Karzinoide Tumoren des Dunndarms. Frankf Z Pathol. 1907; 1: 425-9.
  4. Askanazy M. Zur Pathogenese der Magenkre. bse und über ihren gelegenlialen Keimen in der Magenwand. Dtsch. Med. Wochenschr. 1923; 49: 49-51.
  5. Lehy T., Mignon M., Cadiot G. Gastric endocrine cell behaviourin Zollinger-Ellison patients upon long-term potent antisecretory treatment. Gastroenterology. 1989; 96: 1029-40.
  6. Fischer-Colbrie M., Hagn C., Schober M. Chromogranins A, B and C: widespread constituents of secretory versicles. Ann. N.Y. Acad. Sci. 1987; 493: 120-34.
  7. Grimelius L., Wilander, E. Silver stains in the study of endocrine cells of the gut and pancreas. Invest. Cell Pathol. 1980; 3: 3.
  8. Gladdy R., Strong V., Coit D., Allen P., Gerdes H., Shia J. et al. Defining surgical indications for type I gastric carcinoid tumor. Ann. Surg. Oncol. 2009; 16: 3154-60.
  9. Kölby L., Bernhardt P., Sward C., Johanson V.., Ahlman H., Forssell-Aronsson E. et al. Chromogranin A as a determinant of midgut carcinoid tumour volume. Reg. Pept. 2004; 120: 269-73.
  10. Modlin I.M., Lawton G.P., Miu K. et al. Pathophysiology of the fundic enterochromaffin-like (ECL) cell and gastric carcinoid tumours. Ann. Roy Coll. Surg. Engl. 1996; 78: 133-8.
  11. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010.
  12. Bordi C., D’Adda T., Azzoni C., Ferraro G. Pathogenesis of ECL cell tumors in humans. Yale J. Biol. Med. 1998; 71: 273-84.
  13. Gilligan C.J., Rappel S., Gilligan C.J., Lawton G.P., Tang L.H., West A.B. et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am. J. Gastroenterol. 1995; 90: 338-52.
  14. Bordi C., Yu J.Y., Baggi M.T. et al. Gastric carcinoids and their precursor lesions: a histologic and immunohistochemical study of 23 cases. Cancer. 1991; 67: 663.
  15. Borch K., Ahren B., Ahlman H. et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann. Surg. 2005; 242: 64-73.
  16. Borch K., Renvall H., Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985; 88: 638-48.
  17. Reinecke P., Borchard F. Pattern of gastric endocrine cells in microcarcinoidosis-an immunohistochemical study of 14 gastric biopsies. Virchows Archiv. 1996; 428: 237-41.
  18. Merola E., Sbrozzi-Vanni A., Panzuto F., D’Ambra G., Di Guilio E., Pilozzi E. et al: Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012; 95 (3): 207-13.
  19. Rindi G., Arnold R., Bosman F.T. et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: Bosman F.T. et al. WHO Classification of Tumours of the Digestive System. Lyon: IARC Press; 2010: 13-4.
  20. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J. Surg. 1996; 20: 203-7.
  21. La Rosa S., Inzani F, Vanoli A. et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum. Pathol. 2011; 42: 1373-84.
  22. Rindi G., Bordi C., Rappel S. et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J. Surg. 1996; 20: 168-72.
  23. Norton J.A., Melcher M.L., Gibril F. et al. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004; 136: 1267-74.
  24. Gilligan C.J., Lawton G.P., Tang L.H., West A.B., Modlin I.M. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am. J. Gastroenterol. 1995; 90: 338-52.
  25. Mulkeen A., Cha Ch. Gastric carcinoid. Curr. Opin. Oncol. 2004; 17: 1-6.
  26. Lehy T., Cadiot G., Mignon M., Ruszniewski P., Bonfils S. Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut. 1992; 33: 1275.
  27. Akerstrom G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J. Surg. 1996; 20: 173-82.
  28. Schindl M., Kaserer K., Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch. Surg. 2001; 136: 49-54.
  29. Matsusaka T., Watanabe H., Enjoji M. Oat-cell carcinoma of the stomach. Fukuoka Igaku Zasshi. 1976; 67: 65-73.
  30. Brenner B., Tang L.H., Klimstra D.S., Kelsen D.P. Small-cell carcinomas of the gastrointestinal tract: a review. J. Clin. Oncol. 2004; 22: 2730-9.
  31. Cioppa T., Marrelli D., Neri A., Caruso S., Pedrazzani C., Malagnino V. et al. A case of small-cell gastric carcinoma with an adenocarcinoma component and hepatic metastases: treatment with systemic and intra-hepatic chemotherapy. Eur. J. Cancer Care. 2007; 16: 453-7.
  32. Fukuda T., Ohnishi Y., Nishimaki T., Ohtani H., Tachikawa S. Early gastric cancer of the small cell type. Am. J. Gastroenterol. 1988; 83: 1176-9.
  33. Matsui K., Kitagawa M., Miwa A., Kuroda Y, Tsuji M. Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases. Am. J. Gastroenterol. 1991; 86: 1167-75.

Copyright (c) 2016 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies